Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally. Lupin's key therapeutic areas include pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis. The company is committed to providing affordable and innovative medicines for a healthier world, with a significant presence in research, manufacturing, and marketing across numerous countries.
The Mumbai headquarters serves as the central hub for Lupin's global strategy, corporate governance, research and development oversight, financial management, and key operational decisions.
Located in Kalpataru Inspire, a modern commercial complex, the headquarters features state-of-the-art infrastructure, designed to foster collaboration, innovation, and efficient global management. It likely includes advanced workspaces, meeting facilities, and employee amenities.
Lupin fosters a work culture rooted in its core values of integrity, teamwork, respect for people, customer focus, entrepreneurship, and excellence. The HQ environment is dynamic, research-driven, and focused on achieving global healthcare objectives and improving patient lives.
The headquarters is significant as the command center for one of the world's leading pharmaceutical companies, driving innovation in drug development, managing a vast global supply chain, and steering the company's growth in over 100 countries.
Lupin has a significant global footprint, marketing its products in over 100 countries. Key functions supported globally include Research & Development (with centers in India, USA, Netherlands, Brazil, Mexico), advanced Manufacturing (facilities in India, USA, Mexico, Brazil), Marketing & Sales, a robust Supply Chain network, stringent Quality Assurance, and comprehensive Regulatory Affairs management across all its operational regions.
Lupin Limited, Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East)
Mumbai
Maharashtra
India
Address: Lupin Somerset, 200 Crossing Boulevard, Bridgewater, NJ 08807, USA
Drives growth and market presence in North America, focusing on providing affordable and innovative medicines to patients in the U.S. and Canada. Supports regulatory affairs, strategic partnerships, and product distribution within the region.
Address: Lupin Atlantis Holdings SA, Industriestrasse 1, 6300 Zug, Switzerland
Coordinates Lupin's expansion and market access strategies in Europe, ensuring compliance with regional pharmaceutical regulations and fostering partnerships to enhance product availability.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Lupin' leadership includes:
Lupin has been backed by several prominent investors over the years, including:
Lupin has experienced key leadership transitions over the past 12-18 months, particularly strengthening its U.S. operations with a new CEO and announcing a new Group CFO to steer its global financial strategy. These changes reflect the company's focus on driving growth in key markets and enhancing its leadership capabilities.
Discover the tools Lupin uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Lupin commonly uses professional email address formats that combine an employee's name with the company domain '@lupin.com'. The most prevalent formats include using the first initial followed by the last name, or the full first name separated from the last name by a period.
[firstinitial][lastname]@lupin.com or [firstname].[lastname]@lupin.com
Format
vgupta@lupin.com (example for Vinita Gupta based on common pattern)
Example
85%
Success rate
lupin.com (Press Release) • May 9, 2024
Lupin Limited announced its financial results for the fourth quarter and full year ending March 31, 2024. The company reported strong growth in revenue, particularly in its U.S. operations, and improved profitability, driven by new product launches and enhanced operational efficiencies....more
lupin.com (Press Release) • April 23, 2024
Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Febuxostat Tablets, 40 mg and 80 mg. Febuxostat Tablets are indicated for the chronic management of hyperuricemia in adult patients with gout....more
lupin.com (Press Release) • March 18, 2024
Lupin's subsidiary, Lupin Pharma Canada Ltd., announced the launch of the first generic version of Oracea® (Doxycycline Capsules USP, 40 mg) in Canada, having received approval from Health Canada. This launch expands Lupin's dermatology portfolio in Canada....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Lupin, are just a search away.